Table 4 |
|||
|
CSF biomarkers and neuropathological score in relation to UCHL1 allele A-carrier status in AD patients and control subjects |
|||
|
UCHL1 allele A-carrier status |
|||
|
CSF Biomarker |
positive |
negative |
P-value* |
|
|
|||
|
T-tau (pg/ml), Mean ± SD |
|||
|
AD patients |
640 ± 368 |
613 ± 297 |
0.790 |
|
Controls |
367 ± 175 |
381 ± 156 |
0.528 |
|
P-tau181 (pg/ml), Mean ± SD |
|||
|
AD patients |
80.6 ± 35.1 |
75.3 ± 29.4 |
0.434 |
|
Controls |
58.8 ± 16.7 |
65.7 ± 21.1 |
0.159 |
|
Aβ1-42 (pg/ml), Mean ± SD |
|||
|
AD patients |
406 ± 91.5 |
410 ± 104 |
0.996 |
|
Controls |
749 ± 195 |
703 ± 202 |
0.246 |
|
SPs and NFTs score |
|||
|
Median (25th -- 75th percentiles) |
|||
|
AD patients |
7 (5-8) |
7 (6-9) |
0.495 |
|
Controls |
2 (0-3.5) |
0 (0-2) |
0.122 |
|
|
|||
|
CSF = cerebrospinal fluid, AD = Alzheimer's disease, SPs = senile plaques, NFTs = neurofibrillary tangles, Aβ = β-amyloid, *Mann-Whitney U-test |
|||
|
Zetterberg et al. Molecular Neurodegeneration 2010 5:11 doi:10.1186/1750-1326-5-11 |
|||
